National Advisory Committee on Immunization (NACI) rapid response: Additional dose of COVID-19 vaccine in immunocompromised individuals following 1- or 2- dose primary series

National Advisory Committee on Immunization (NACI) rapid response: Additional dose of COVID-19 vaccine in immunocompromised individuals following 1- or 2- dose primary series The National Advisory Committee on Immunization (NACI) is an External Advisory Body that provides the Public Health Agency of Canada (PHAC) with independent, ongoing and timely medical, scientific, and public health advice in response to questions from PHAC relating to immunization. This statement contains NACI's independent advice and recommendations, which are based upon the best current available scientific knowledge. This document is being disseminated for information purposes. People administering the vaccine should also be aware of the contents of the relevant product monograph. Recommendations for use and other information set out herein may differ from that set out in the product monographs of the Canadian manufacturers of the vaccines. Manufacturer(s) have sought approval of the vaccines and provided evidence as to its safety and efficacy only when it is used in accordance with the product monographs. NACI members and liaison members conduct themselves within the context of PHAC's Policy on Conflict of Interest, including yearly declaration of potential conflict of interest. 2021-11-05 Public Health Agency of Canada open-ouvert@tbs-sct.gc.ca Health and SafetypandemicCOVID-19CoronavirusCOVIDVaccinesimmunizationNationalAdvisoryCommitteeImmunizationNACIStatementspublicationsRecommendationson the useof COVID-19vaccinesrapidresponseAdditionaldosevaccineimmunocompromisedindividuals1 dose2 doseprimaryseriesMethodsCIConfidence intervalcoronavirus disease2019mRNAmessengerribonucleic acidPHACPublicHealthAgencyCanadaSARS-CoV-2SevereAcuteRespiratorySyndromeCoronavirus 2SummaryevidenceBurdenillness2-doseseriesadditionaldoseAdditionalinformationconsiderationsRecommendationsResearchprioritiesReferencesAbbreviations National Advisory Committee on Immunization (NACI) rapid response: Additional dose of COVID-19 vaccine in immunocompromised individuals following 1- or 2- dose primary seriesHTML https://www.canada.ca/en/public-health/services/immunization/national-advisory-committee-on-immunization-naci/statement-september-10-2021-additional-dose-covid-19-vaccine-immunocompromised-following-1-2-dose-series.html National Advisory Committee on Immunization (NACI) rapid response: Additional dose of COVID-19 vaccine in immunocompromised individuals following 1- or 2- dose primary seriesHTML https://www.canada.ca/fr/sante-publique/services/immunisation/comite-consultatif-national-immunisation-ccni/declaration-10-septembre-2021-dose-supplementaire-vaccin-covid-19-immunocomprimes-apres-series-1-2-doses.html

The National Advisory Committee on Immunization (NACI) is an External Advisory Body that provides the Public Health Agency of Canada (PHAC) with independent, ongoing and timely medical, scientific, and public health advice in response to questions from PHAC relating to immunization.

This statement contains NACI's independent advice and recommendations, which are based upon the best current available scientific knowledge. This document is being disseminated for information purposes. People administering the vaccine should also be aware of the contents of the relevant product monograph. Recommendations for use and other information set out herein may differ from that set out in the product monographs of the Canadian manufacturers of the vaccines. Manufacturer(s) have sought approval of the vaccines and provided evidence as to its safety and efficacy only when it is used in accordance with the product monographs. NACI members and liaison members conduct themselves within the context of PHAC's Policy on Conflict of Interest, including yearly declaration of potential conflict of interest.

Data and Resources

Similar records